DS
APGE icon

David Shaw’s Apogee Therapeutics APGE Stock Holding History

David Shaw’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.7M Buy
246,086
+187,251
+318% +$16.9M 0.02% 998
2026
Q1 		$4.95M Sell
58,835
-4,415
-7% -$321K ﹤0.01% 2183
2025
Q4 		$4.77M Sell
63,250
-37,320
-37% -$2.35M ﹤0.01% 2345
2025
Q3 		$4M Sell
100,570
-93,958
-48% -$3.59M ﹤0.01% 2415
2025
Q2 		$8.45M Buy
194,528
+185,752
+2,117% +$7.07M 0.01% 1626
2025
Q1 		$328K Sell
8,776
-1,037
-11% -$40.1K ﹤0.01% 3729
2024
Q4 		$445K Sell
9,813
-39,849
-80% -$2.03M ﹤0.01% 3689
2024
Q3 		$2.92M Sell
49,662
-2,364
-5% -$113K ﹤0.01% 2402
2024
Q2 		$2.05M Buy
+52,026
New +$2.53M ﹤0.01% 2638

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

David Shaw's APGE Position: Q2 2026 in Review

David Shaw increased its Apogee Therapeutics (APGE) stake by 318% in Q2 2026, buying an estimated $16.9M and bringing the position to 246,086 shares worth $32.7M. The position accounts for 0.02% of the portfolio, ranked #998.

David Shaw first reported a position in APGE in Q2 2024 and has held it in 9 quarters since. 286 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • David Shaw held 246,086 shares of Apogee Therapeutics worth $32.7M as of Q2 2026.
  • David Shaw bought 187,251 Apogee Therapeutics shares in Q2 2026, an estimated $16.9M.
  • Apogee Therapeutics made up 0.02% of David Shaw's portfolio in Q2 2026, its #998 holding.
  • David Shaw first reported a position in Apogee Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • 286 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.